Immunomedics Inc. on Tuesday reported results from a PhaseII clinical trial of its imaging agent for the detection of non-HodgkinLs B-cell lymphoma. The trial showed that theapplication of ImmuRAID-LL2 resulted in an imagingsensitivity of nearly 100 percent in one patient group, correctlyidentifying at least one known lesion in each of the 10 patients.
The data were presented at the Fifth Annual Symposium,Diagnostic and Therapeutic Applications of Antibodies, Peptidesand Molecular Recognition Units in Nuclear Medicine in FortLauderdale, Fla. Based on the Phase II findings, the company isplanning Phase III trials with the agent.
(c) 1997 American Health Consultants. All rights reserved.